Bitcoin price today: falls to 2-week low below $113k ahead of Fed Jackson Hole
Harrison Robert Gardner, the Chief Information Officer of Sera Prognostics , Inc. (NASDAQ:SERA), recently sold 554 shares of the company's Class A common stock. The shares were sold at a weighted average price of $3.97, totaling approximately $2,199. The transaction occurred near the stock's 52-week low of $3.84, with the company's market capitalization currently standing at $144.21 million. According to InvestingPro analysis, the stock's RSI suggests oversold conditions. This transaction, executed on February 11, 2025, was carried out under a Rule 10b5-1 trading plan that Gardner adopted on May 14, 2024. Following the sale, Gardner retains ownership of 114,019 shares in the company. The stock has experienced significant pressure, down 52.4% over the past year. InvestingPro subscribers have access to 8 additional key insights about SERA, including detailed financial health metrics and comprehensive analysis available in the Pro Research Report.
In other recent news, Sera Prognostics, a medical laboratory services provider, has halted its $50 million stock offering. The company had previously intended to sell up to $50 million of its Class A common stock through TD Securities but has now terminated this plan, according to a recent SEC filing. However, the sales agreement with TD Cowen remains effective, and Sera Prognostics reserves the right to initiate a new offering after filing a new prospectus or prospectus supplement.
In a separate development, Sera Prognostics has launched a public offering of its Class A common stock and pre-funded warrants. The company plans to use the proceeds to expand U.S. commercial operations, prepare for EU growth, seek FDA approval for its PreTRM test, and other corporate purposes. The offering is managed by Jefferies, TD Cowen, William Blair, and RBC Capital Markets.
Moreover, Sera Prognostics recently announced that the Society for Maternal Fetal Medicine has published an abstract with topline results from the PRIME study. The results of the study, which focuses on improving neonatal outcomes through prematurity risk assessment combined with clinical interventions, are set to be presented later this month. Following the presentation, Sera Prognostics plans to host a conference call and live audio webcast for a more in-depth discussion of the study's outcomes. These are the latest developments for Sera Prognostics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.